FLC输注在中晚期实体瘤治疗中的应用──附36例分析  

The Application of Fetal Liver Cell Transfusion in Patients with Moderate and Advanced Solid Tumor

作　　者：郭良君[1] 庄承海[1] 王奕鸣[1] 李平[1] 

机构地区：[1]暨南大学医学院附属医院肿瘤科

出　　处：《肿瘤防治研究》1996年第6期352-354,共3页Cancer Research on Prevention and Treatment

摘　　要：本文报道了胎肝细胞悬液输注在３６例中晚期实体瘤治疗中的应用。临床观察结果表明：胎肝细胞输注能明显缓解化疗药物对骨髓的抑制，并刺激造血功能恢复，外周血象回升快，能提高免疫功能，改善一般症状，对配合化、放疗，延长生存期均有较好效果。在恶性肿瘤治疗中是一种值得选用的积极有效的辅助治疗。Thirty-six cases of patients with moderate and advanced solid tumor treated with Fetal Lital Cell (FCL) Transfusion. The result showed that the FLC transfusion can retrieve myelosuppression caused by chemotherapic durgs obviously and promote the fuctions of hematopoiesis and immunity. The peripheral blood picture and general symptoms of the patients can be improved rapidly. FLC transfusion can provide a fevourable condition for chemotherapy or radiotherapy and prolonge the sarvival times.

关 键 词：胎肝细胞输注 实体瘤 治疗 中晚期 

分 类 号：R730.51[医药卫生—肿瘤]